



# Humanized Anti-PEG monoclonal antibody, clone H7.4 (CABT-L3142)

This product is for research use only and is not intended for diagnostic use.

## PRODUCT INFORMATION

Product Overview	Recombinant antibody composed of humanized 7.4 VH and VL with human IgG1 constant regions
Specificity	This is a humanized form of the high affinity clone 7.4 anti-PEG antibody.
Target	This antibody binds to the backbone of PEG and can be detected with anti-human secondary antibodies.
Isotype	IgG1
Source/Host	Human
Species Reactivity	N/A
Clone	H7.4
Purification	Affinity Purified
Conjugate	Unconjugated
Applications	ELISA
Format	Liquid
Concentration	Lot specific
Size	50 μg
Buffer	Purified antibdoy supplied in 50% glycerol and phosphate buffered saline (0.14 M NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4)

45-1 Ramsey Road, Shirley, NY 11967, USA

Tel: 1-631-624-4882 Fax: 1-631-938-8221

Preservative	0.04% Sodium Azide
Storage	Long time storage is recommended at -20°C.
Ship	Wet ice

### **BACKGROUND**

#### Introduction

PEG (polyethylene glycol) is a water-soluble, nontoxic, biocompatible polymer that has been approved by the Food and Drug Administration (FDA) for human intravenous, oral and dermal applications. Attachment of PEG chains to proteins can reduce their immunogenicity, minimize proteolytic cleavage and increase their serum half-life. PEG has also been attached to small molecules and liposomes for more selective delivery. PEG-modification of superparamagnetic iron oxide and quantum dots can improve their biocompatibility and reduce non-specific uptake. PEG antibodies can be a vital tool for propelling therapeutics to market by serving as a positive control anti-drug antibody, measuring clearance of a drug, or simply as a QA release confirming PEGylation.

#### Keywords

Polyetheylene Glycol; PEG